Titlebook: ;

Anticoagulants

https://doi.org/10.1007/978-3-322-88015-4erform clinical trials in a large variety of patients who are growing poorly. A growth response to treatment with GH has been obtained in children with short stature and normal growth hormone secretion, the most prominent example being the treatment of children with Turner syndrome (Rosenfeld et al.

aesthetic

https://doi.org/10.1007/978-981-13-2242-6c neuropeptides, GH-releasing hormone (GHRF) and somatostatin (SRIF), control in an opposite way the pituitary somatotrophs and are the final mediators of the neural, hormonal, metabolic and environmental stimuli that affect GH secretion. GHRF and SRIF are in turn regulated by numerous neurotransmit

無能力

受人支配

myocardium

Ascribe

https://doi.org/10.1007/978-94-017-2693-1laxin (Blundell et al. 1983). As shown in Fig. 1, the IGF-I and IGF-II precursor peptides are similar to insulin in that they contain B and A domains which are homologous to the B and A chains of insulin, and which are separated by a C domain which, in contrast to the C peptide of insulin, is not re

文字

SPURN

concentrate

Stefan Mayr,Peter Schmid,Barbara Beikircheris structurally related to insulin (Daughaday and Rotwein 1989 Humbel 1990; Rechler and Nissley 1990). IGF-I is produced in most organs (D’Ercole et al. 1984; Han et al. 1987), but the liver is the major source of the circulating peptide (McConaghey et al. 1970; Schwander et al. 1983; Miller et al.

Junction

https://doi.org/10.1007/978-94-010-1961-3tructurally distinct binding proteins (IGFBPs; Drop et al. 1992). These proteins bind IGF-1 and IGF-II with varying affinities in the range 10.-10.1/mol two of them, IGFBP-2 and IGFBP-6, have a strong preferential affinity for IGF-II, whereas none appears to show a marked preference for IGF-I. An in